Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | TYR | P14679 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | KRAS | P01116 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231449 | 1.00 | CA12 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL7240019 | 0.95 | MAOB (0.57) | CA12CA1CA2TYRCA7 | |
| Alcohol SCHEMBL6171481 | 0.94 | KMT2A (0.56) | CA12CA1CA2TYRCA7 | |
| SCHEMBL29082929 | 0.93 | MAOB (0.61) | CA12CA1CA2TYRCA7 | |
| SCHEMBL10543256 | 0.88 | MAOB (0.56) | MAOBMAOAKMT2AMEN1PTGS2 | |
| SCHEMBL5057418 | 0.84 | CA12 (0.84) | CA12CA1CA2TYRCA7 | |
| SCHEMBL71224 | 0.84 | CA12 (0.84) | CA12CA1CA2TYRCA7 | |
| SCHEMBL6841705 | 0.83 | MAPT (0.49) | CA12CA1CA2TYRCA7 | |
| SCHEMBL9523424 | 0.83 | MAOB (0.61) | MAOBMAOAKMT2AMEN1PTGS2 | |
| SCHEMBL15367534 | 0.83 | MAOB (0.61) | MAOBMAOAKMT2AMEN1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | claimed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | claimed |
| US-20170242174-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORPORATION (JP) | 2017-08-24 | — | — | US | claimed |
| EP-3208301-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | Tosoh Corporation (JP) | 2017-08-23 | — | — | EP | claimed |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | UNIVERSITÉ CLERMONT AUVERGNE (FR) | 2015-10-01 | — | — | US | claimed |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) | 2015-02-05 | — | — | US | claimed |
| CN-101774918-A | Preparation method of cinnamate derivates | UNIV HUAQIAO | 2010-07-14 | — | — | CN | claimed |
| CN-110694652-A | Method for generating ester compound by catalytic oxidation of ether compound with visible light excited silver iodide and bismuth vanadate composite material | 潍坊医学院 | 2020-01-17 | — | — | CN | disclosed |
| CN-106795327-B | Resin composition and optical compensation film using the same | 东曹株式会社 | 2019-08-30 | — | — | CN | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3246309-A1 | METHOD FOR TREATING TIN COMPOUND IN REACTION MIXTURE | Nissan Chemical Industries, Ltd. (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-5767304-A | USING OSMIUM CATALYST AND CHIRAL LIGAND | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1997046516-A1 | CATALYTIC ASYMMETRIC AMINOHYDROXYLATION OF OLEFINS WITH CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-11 | — | — | WO | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4051177-A | PROCESS FOR THE PREPARATION OF UNSATURATED AMINO COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4002673-A | GROUP VIII METAL SULFIDE AS HYDROGENATION CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | CA12 2097/4885CA1 2896/4885CA2 2540/4885 |
| US-20150038466-A1 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | CA12 1462/4885CA1 324/4885CA2 332/4885 |
| US-20150274633-A2 | PAIN RELIEF COMPOUNDS | OPRL1, OPRK1, TRPV1 | CA12 1462/4885CA1 324/4885CA2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.